The insulin‐like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild‐type epidermal growth factor receptor
Kenichi Suda(Izumi City General Hospital), Tetsuya Mitsudomi(Kindai University)
Cited by 53
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Reduced Expression of the <b> <i>let-7</i> </b> MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
|Cancer Research|2004|2.4k